Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Tom Waddell; Ian Chau; David Cunningham; David Gonzalez; Alicia Frances Clare Okines; Alicia Frances; Clare Okines; Andrew Wotherspoon; Claire Saffery; Gary Middleton; Jonathan Wadsley; David Ferry; Wasat Mansoor; Tom Crosby; Fareeda Coxon; David Smith; Justin Waters; Timothy Iveson; Stephen Falk; Sarah Slater; Clare Peckitt; Yolanda Barbachano

doi:10.1016/S1470-2045(13)70096-2

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Tom Waddell, Ian Chau, David Cunningham, David Gonzalez, Alicia Frances Clare Okines, Alicia Frances, Clare Okines, Andrew Wotherspoon, Claire Saffery, Gary Middleton, Jonathan Wadsley, David Ferry, Wasat Mansoor, Tom Crosby, Fareeda Coxon, David Smith, Justin Waters, Timothy Iveson, Stephen Falk, Sarah SlaterClare Peckitt, Yolanda Barbachano

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

502 Citations (Scopus)

Abstract

EGFR overexpression occurs in 27-55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagogastric adenocarcinoma.

Original language	English
Pages (from-to)	481-9
Number of pages	9
Journal	The Lancet Oncology
Volume	14
Issue number	6
DOIs	https://doi.org/10.1016/S1470-2045(13)70096-2
Publication status	Published - May 2013

Bibliographical note

Keywords

Adenocarcinoma
Aged
Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols
Chi-Square Distribution
Deoxycytidine
Disease-Free Survival
Early Termination of Clinical Trials
Epirubicin
Esophageal Neoplasms
Female
Fluorouracil
Great Britain
Humans
Intention to Treat Analysis
Kaplan-Meier Estimate
Logistic Models
Male
Middle Aged
Molecular Targeted Therapy
Multivariate Analysis
Odds Ratio
Organoplatinum Compounds
Proportional Hazards Models
Protein Kinase Inhibitors
Receptor, Epidermal Growth Factor
Stomach Neoplasms
Time Factors
Treatment Outcome
Tumor Markers, Biological

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(13)70096-2

Cite this

Waddell, T., Chau, I., Cunningham, D., Gonzalez, D., Okines, A. F. C., Frances, A., Okines, C., Wotherspoon, A., Saffery, C., Middleton, G., Wadsley, J., Ferry, D., Mansoor, W., Crosby, T., Coxon, F., Smith, D., Waters, J., Iveson, T., Falk, S., ... Barbachano, Y. (2013). Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. The Lancet Oncology, 14(6), 481-9. https://doi.org/10.1016/S1470-2045(13)70096-2

@article{c8471dabf8bd4554b9c730cc3058d5ef,

title = "Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial",

abstract = "EGFR overexpression occurs in 27-55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagogastric adenocarcinoma.",

keywords = "Adenocarcinoma, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Chi-Square Distribution, Deoxycytidine, Disease-Free Survival, Early Termination of Clinical Trials, Epirubicin, Esophageal Neoplasms, Female, Fluorouracil, Great Britain, Humans, Intention to Treat Analysis, Kaplan-Meier Estimate, Logistic Models, Male, Middle Aged, Molecular Targeted Therapy, Multivariate Analysis, Odds Ratio, Organoplatinum Compounds, Proportional Hazards Models, Protein Kinase Inhibitors, Receptor, Epidermal Growth Factor, Stomach Neoplasms, Time Factors, Treatment Outcome, Tumor Markers, Biological",

author = "Tom Waddell and Ian Chau and David Cunningham and David Gonzalez and Okines, {Alicia Frances Clare} and Alicia Frances and Clare Okines and Andrew Wotherspoon and Claire Saffery and Gary Middleton and Jonathan Wadsley and David Ferry and Wasat Mansoor and Tom Crosby and Fareeda Coxon and David Smith and Justin Waters and Timothy Iveson and Stephen Falk and Sarah Slater and Clare Peckitt and Yolanda Barbachano",

year = "2013",

month = may,

doi = "10.1016/S1470-2045(13)70096-2",

language = "English",

volume = "14",

pages = "481--9",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier",

number = "6",

}

Waddell, T, Chau, I, Cunningham, D, Gonzalez, D, Okines, AFC, Frances, A, Okines, C, Wotherspoon, A, Saffery, C, Middleton, G, Wadsley, J, Ferry, D, Mansoor, W, Crosby, T, Coxon, F, Smith, D, Waters, J, Iveson, T, Falk, S, Slater, S, Peckitt, C & Barbachano, Y 2013, 'Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial', The Lancet Oncology, vol. 14, no. 6, pp. 481-9. https://doi.org/10.1016/S1470-2045(13)70096-2

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. / Waddell, Tom; Chau, Ian; Cunningham, David et al.
In: The Lancet Oncology, Vol. 14, No. 6, 05.2013, p. 481-9.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3)

T2 - a randomised, open-label phase 3 trial

AU - Waddell, Tom

AU - Chau, Ian

AU - Cunningham, David

AU - Gonzalez, David

AU - Okines, Alicia Frances Clare

AU - Frances, Alicia

AU - Okines, Clare

AU - Wotherspoon, Andrew

AU - Saffery, Claire

AU - Middleton, Gary

AU - Wadsley, Jonathan

AU - Ferry, David

AU - Mansoor, Wasat

AU - Crosby, Tom

AU - Coxon, Fareeda

AU - Smith, David

AU - Waters, Justin

AU - Iveson, Timothy

AU - Falk, Stephen

AU - Slater, Sarah

AU - Peckitt, Clare

AU - Barbachano, Yolanda

PY - 2013/5

Y1 - 2013/5

N2 - EGFR overexpression occurs in 27-55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagogastric adenocarcinoma.

AB - EGFR overexpression occurs in 27-55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagogastric adenocarcinoma.

KW - Adenocarcinoma

KW - Aged

KW - Antibodies, Monoclonal

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Chi-Square Distribution

KW - Deoxycytidine

KW - Disease-Free Survival

KW - Early Termination of Clinical Trials

KW - Epirubicin

KW - Esophageal Neoplasms

KW - Female

KW - Fluorouracil

KW - Great Britain

KW - Humans

KW - Intention to Treat Analysis

KW - Kaplan-Meier Estimate

KW - Logistic Models

KW - Male

KW - Middle Aged

KW - Molecular Targeted Therapy

KW - Multivariate Analysis

KW - Odds Ratio

KW - Organoplatinum Compounds

KW - Proportional Hazards Models

KW - Protein Kinase Inhibitors

KW - Receptor, Epidermal Growth Factor

KW - Stomach Neoplasms

KW - Time Factors

KW - Treatment Outcome

KW - Tumor Markers, Biological

U2 - 10.1016/S1470-2045(13)70096-2

DO - 10.1016/S1470-2045(13)70096-2

M3 - Article

C2 - 23594787

SN - 1470-2045

VL - 14

SP - 481

EP - 489

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 6

ER -

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this